Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Chemotherapy-induced hemolytic uremic syndrome in locally advanced cervical cancer treated with combination chemotherapy after laparoscopic radical hysterectomy: a case report and review of the literature
1 Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea
2 Department of Obstetrics and Gynecology, University of Inje College of Medicine, Haeundae Paik Hospital, Busan, Korea
Eur. J. Gynaecol. Oncol. 2017, 38(6), 956–959; https://doi.org/10.12892/ejgo3542.2017
Published: 10 December 2017
Hemolytic uremic syndrome (HUS) is a rare complication of chemotherapy characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure without disseminated intravascular coagulation. Although few cases of chemotherapy-induced HUS have been reported in gynecologic malignancy, it can be a fulminant, chronic disease and can be managed with early aggressive treatment. A 38-year-old woman was diagnosed with FIGO Stage IIb squamous cell carcinoma of the uterine cervix. After three cycles of neoadjuvant chemotherapy that consisted of a combined regimen of mytomicin-C, vincristine, and cisplatin, a laparoscopic radical hysterectomy was performed, and the pathological diagnosis of the residual lesion was deep stromal invasion. Following two adjuvant courses of the same chemotherapy, she developed chemotherapy-induced HUS. The patient was aggressively treated with therapeutic plasma exchange with fresh-frozen plasma and a high dose of steroids. At the last follow-up, the serum creatinine level had decreased to 1.81 mg/dl, and evidence of recurrence was not found.
Hemolytic uremic syndrome
Therapeutic plasma exchange